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SUMMARY
Background
Primary analysis of the Hepatitis C Antiviral Long-Term Treatment
against Cirrhosis (HALT-C) Trial showed long-term peginterferon ther-
apy did not reduce complications in patients with chronic hepatitis C
and advanced fibrosis or cirrhosis.
Aim
To assess the effects of long-term peginterferon therapy and disease
progression on health-related quality of life (HRQOL), symptoms and
sexual health in HALT-C patients.
Methods
A total of 517 HALT-C patients received peginterferon alfa-2a (90 lg ⁄
week); 532 received no additional treatment for 3.5 years. Patients were
followed up for outcomes of death, hepatocellular carcinoma and hepatic
decompensation. Sexual health, SF-36 scores and symptoms were serially
assessed by repeated-measures analyses of covariance.
Results
Patients with cirrhosis (n = 427) reported lower general well-being and
more fatigue (P < 0.001) than patients with fibrosis (n = 622). Physical
scores declined significantly over time, independent of treatment, and
patients with cirrhosis reported lower scores. Vitality scores were lower in
those with cirrhosis, and treated patients experienced a greater decline over
time than untreated patients; HRQOL rebounded after treatment ended.
Patients with a clinical outcome had significantly greater declines in all
SF-36 and symptom scores. Among men, Sexual Health scores were signif-
icantly worse in treated patients and in those with a clinical outcome.
Conclusion
Clinical progression of chronic hepatitis C and maintenance peginterferon
therapy led to worsening of symptoms, HRQOL and, in men, sexual health
in a large patient cohort followed up over 4 years (NCT00006164).
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INTRODUCTION
Chronic hepatitis C (CHC) is a leading cause of chronic
liver disease, liver failure and hepatocellular carci-
noma (HCC) in the US and other Western countries.1
Among the estimated 3.2 million adult Americans
infected chronically with hepatitis C virus (HCV),
many are unaware of their infections because they
lack clinically apparent signs or symptoms.2 With dis-
ease progression, however, patients may experience
various nonspecific symptoms such as fatigue, nausea
and right upper quadrant pain.3–6 In addition, many
patients with CHC report reduced quality of life
although the relationship with disease severity is mod-
est and at times inconsistent.7–13 The weak correlation
of liver disease severity and clinical symptoms with
quality of life in patients with CHC may result, in part,
from the influence of other commonly encountered
medical and psychiatric comorbidities, such as diabetes
mellitus and depression.14, 15
Several longitudinal studies of interferon therapy in
patients with CHC have shown improvements in
health-related quality of life (HRQOL) in patients who
are able to achieve a sustained virological response
(SVR) compared with nonresponders and relaps-
ers.10, 11, 16–35 Whether these improvements resulted
from a sustained loss of viral replication or from the
psychological improvement following the cure of a
chronic disease and an improvement in prognosis
remains unknown. Because of the slow rate of disease
progression and the resultant need to follow a large
number of patients prospectively for several years,
none of these studies demonstrated an association
between objective disease progression and worsening
symptoms or HRQOL. Sexual dysfunction associated
with CHC has also been reported,36, 37 but the relation-
ship between sexual dysfunction and disease severity
or progression has not been well defined. Furthermore,
psychological concerns about harbouring an infectious
disease that can be transmitted to others may
influence sexual health parameters in patients with
CHC.
Recently, the Hepatitis C Antiviral Long-Term Treat-
ment against Cirrhosis (HALT-C) Trial demonstrated
that maintenance peginterferon therapy did not reduce
the rate of clinical or histological disease progression
in patients with CHC and advanced fibrosis, with or
without cirrhosis, who did not have a response to
initial treatment with peginterferon and ribavirin.38
During the trial, prospective assessment of symptoms
and HRQOL was incorporated as a planned secondary
outcome. We hypothesized that because of the side
effect profile of interferon therapy, prolonged treat-
ment with low-dose peginterferon would be difficult
to tolerate and therefore associated with worsening
fatigue, reduced general well being and reductions in
HRQOL. In addition, we set out to measure the impact
of maintenance peginterferon therapy on sexual
health. We have previously shown that (i) HALT-C
participants with cirrhosis had lower HRQOL scores
than participants with noncirrhotic fibrosis at entry
into the study and (ii) HALT-C participants who
achieved an SVR after peginterferon ⁄ ribavirin therapy
had improved HRQOL and Sexual Health scores.22 The
current analyses summarize the results of the assess-
ment of symptoms, HRQOL and sexual enjoyment,
desire, and function before, during and after the
randomized phase of the trial, focusing on the




The design of the HALT-C Trial and its major out-
comes have been described previously.38, 39 Briefly,
patients with CHC and advanced fibrosis, with or with-
out cirrhosis, who had failed to respond to a previous
course of antiviral therapy, were enrolled into the trial
at 10 study centres in the US. Enrolment criteria
included age of 18 years or older; the presence of HCV
RNA in serum; failure to achieve an SVR with a previ-
ous adequate course of combination antiviral therapy;
advanced hepatic fibrosis on liver biopsy (Ishak stage
‡3 fibrosis)40 stratified into a noncirrhotic fibrosis
group (stage 3 or 4) and a cirrhosis group (stage 5 or
6); no history of hepatic decompensation or HCC; and
the absence of various exclusion criteria including
uncontrolled medical or psychiatric conditions, inter-
feron intolerance and active use of illicit drugs or
alcohol abuse.39
After baseline evaluation, patients were retreated
during a ‘lead-in’ phase with peginterferon alfa-2a
(180 lg weekly; Pegasys; Roche Pharmaceuticals, Nut-
ley, NJ, USA) and ribavirin (1000–1200 mg daily; Co-
pegus; Roche). Patients with detectable serum HCV
RNA levels at week 20 were classified as nonresponders
and were randomized at week 24 into either the main-
tenance-therapy group (90 lg of peginterferon alfa-2a
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weekly without ribavirin) or the untreated control
group. Patients with undetectable serum HCV RNA at
week 20 continued therapy for 48 weeks.41 If HCV RNA
was detected again after week 20, either during treat-
ment (breakthrough) or after cessation of treatment
(relapse), the patient was offered the opportunity to
undergo randomization into the HALT-C Trial (‘break-
through or relapse’ cohort). During the trial, the proto-
col was amended to allow patients who had failed
treatment with peginterferon plus ribavirin outside the
study to undergo randomization (‘express’ cohort).
Treatment ceased per protocol at study month 48.
Study endpoints
Primary clinical outcomes included death, hepatic
decompensation (variceal haemorrhage, ascites, spon-
taneous bacterial peritonitis or hepatic encephalopa-
thy), HCC, a Child–Turcotte–Pugh score42 of ‡7 on
two consecutive study visits and for patients with non-
cirrhotic fibrosis at baseline, an increase in the Ishak
fibrosis score of ‡2 points according to assessment of
liver-biopsy specimens obtained during the study.
During the randomized phase of the trial, patients
were seen every 3 months to obtain a medical history,
physical examination and laboratory testing to moni-
tor the effects of peginterferon therapy and to assess
for clinical endpoints and adverse events. The patients
underwent hepatic ultrasound every 12 months to
screen for HCC, as well as liver biopsy at baseline and
study months 24 and 48. After trial completion at
study month 48, patients were followed up at 6-month
intervals. The study was approved by local institu-
tional review boards and all patients provided written
informed consent.
HRQOL and sexual health questionnaires
To measure HRQOL, we administered the highly reli-
able and validated Short Form Health Survey
(SF-36)43 at annual study visits. The SF-36 Physical
and Mental Summary scales (0 = worst; 100 = best)
are standardized around a population mean score of
50. Observed differences of three points or greater on
the measured scales are considered clinically signifi-
cant.44 Three questions that addressed self-reported
sexual satisfaction and enjoyment, desire and interest,
and functioning and performance were added to the
SF-36 (Appendix A). The composite Sexual Health
Scale was calculated as the mean of completed items
in the scale (0 = worst; 100 = best) and was not
adjusted to reflect a population mean.22
Symptom questionnaire
We asked study patients to rank their clinical symp-
toms on a self-administered 10-cm visual analogue
scale, with the score equalling the measured distance
from the 0-cm left mark (Appendix A).45 For these
analyses, we analysed the baseline and annual symp-
tom scores for fatigue (none = 0 cm to worst ever =
10 cm) and general well-being (‘how you feel overall’,
very good = 0 cm to very bad = 10 cm).
Data analyses
Statistical analyses were performed at the Data Coordi-
nating Center (New England Research Institutes, Water-
town, MA, USA) using SAS software, version 9.1 (SAS
Institute, Cary, NC, USA). Complete baseline data of
1049 of the 1050 randomized patients were analysed.
There were six response variables: two symptom scores,
three SF-36 scales and the Sexual Health Scale. The
response variables were assessed at study months 0
(baseline), trial months 12, 24, 36, 48 and study month
54 (6 months post-trial). Repeated-measures analyses
of covariance (ANCOVAs) were used to investigate
changes in each of the six response variables over time
controlling for baseline level of the variable, stratum
(cirrhosis ⁄ noncirrhotic fibrosis), randomization assign-
ment (treatment ⁄ control), time, age, gender and race as
fixed effects. For any factors significantly associated
with a response variable, we tested the interaction of
that factor and time. The Conditional Model Concor-
dance Correlation Coefficient was used for assessing the
adequacy of each model;46 the coefficient can range
from )1 to 1 and a value £0 indicates poor fit.
To evaluate the association of clinical and histologi-
cal outcomes with the response variables, we included
a time varying covariate with two categories: whether
or not patient met the definition of any outcome at or
before the date of the visit at which the response vari-
able was assessed. The patient’s first outcome (includ-
ing death) was used for analyses. The covariate was
added to each model as a predictor after controlling
for stratum (cirrhosis ⁄ noncirrhotic fibrosis), random-
ization assignment, time, age, gender, race and base-
line level of the response variable. Patients lost to
follow-up (including those who died) provided no
information after the point they were lost. For analyses
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of histological progression (‡2-point increase in Ishak
fibrosis score), we analysed only patients in the non-
cirrhotic fibrosis stratum with at least one follow-up
biopsy. For the Sexual Health Scale, separate analyses
were performed for male and female subjects.
RESULTS
Characteristics of cohort
A flowchart of participants enrolled in the HALT-C
Trial and the 1049 with complete baseline data
included in these analyses is shown in Figure 1. At
entry, the mean age of the participants was 50.1  7.2
years, 71% were men and 72% were non-Hispanic
Whites (Table 1). One-third of participants (34%) were
taking antidepressant or anxiolytic medications at
baseline. Although most participants had previously
used alcohol (83%) or smoked cigarettes (76%), few
were still drinking (17%) or smoking (30%) at baseline.
At baseline, 622 participants (59%) had noncirrhotic
fibrosis (Ishak 3–4) and 427 (41%) had cirrhosis (Ishak
5–6). The mean body mass index was higher and HCV
RNA levels were lower in participants with cirrhosis
than in those with fibrosis, while the other clinical
and demographic features were similar in the fibrosis
and cirrhosis groups. No major differences were pres-
ent at baseline between the treatment and control
groups (data not shown).
Changes in symptoms and scores over time
Table 2 shows the slope coefficients derived from the
final ANCOVA models for the association of each
49 were not eligible for randomization 
12 refused randomization
70 withdrew or lost to follow-up 
 11 withdrew immediately 
 21 withdrew at ≤24 months
38 withdrew at 25–48 months
157 discontinued peginterferon  
516 were assigned to treatment group
81 withdrew or lost to follow-up 
 10 withdrew immediately 
 34 withdrew at ≤24 months
37 withdrew at 25–48 months 
9 took peginterferon outside of protocol 
533 were assigned to control group
Lead-in
1432 patients were 
assessed for enrollment 
233 were not eligible for Lead-in 
  54 declined to participate 
230 were not eligible for randomization 
102 refused randomization 
Express
298 patients were 
assessed for enrollment 
813 (56.8%) underwent randomization 
813 completed Baseline HRQOL/ 
 symptoms questionnaires 
237 (79.5%) underwent randomization 
236 completed baseline HRQOL/ 
 symptoms questionnaires 
1050 underwent randomization 
447 completed the study (Month 48) 
490 completed month 12 HRQOL/Symptoms 
470 completed month 24 HRQOL/Symptoms 
447 completed month 36 HRQOL/Symptoms 
411 completed month 48 HRQOL/Symptoms 
363 completed month 54 HRQOL/Symptoms 
452 completed the study (Month 48) 
495 completed month 12 HRQOL/Symptoms  
475 completed month 24 HRQOL/Symptoms  
453 completed month 36 HRQOL/Symptoms  
425 completed month 48 HRQOL/Symptoms  
381 completed month 54 HRQOL/Symptoms  
Figure 1. Enrolment, randomization, and follow-up of study participants. Patients were enrolled in either the lead-in cohort
of patients who underwent another course of antiviral treatment with peginterferon and ribavirin within the study or in the
express cohort of patients who were initially treated outside the study. They were then randomly assigned to either the
treatment or the control group and were followed up for clinical outcomes and histological evidence of progression of liver
disease.
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patient characteristic with the six response variables
(symptoms, SF-36 and Sexual Health scores). None of
the interaction effects of patient characteristics by
time was statistically significant. Thus, each slope
coefficient estimates the difference in the response
variable at each value of the patient characteristic
averaged over the entire time period. For categorical
predictors (such as gender), the coefficient represents
the difference between the average level of response
variable in two groups. For continuous predictors
(such as age), the coefficient represents the relation-
ship of the average level of response variable to the
average level of predictor. The Conditional Model
Concordance Correlation Coefficient was consistent
with adequate to good fit of each model. At month
12, 21 participants had experienced a clinical out-
come (2 in the fibrosis stratum and 19 in the cirrhosis
stratum). At month 54, 85 participants had experi-
enced a clinical outcome (28 in the fibrosis stratum
and 57 in the cirrhosis stratum).
Table 1. Selected demographic and historical features of participants
All patients
(n = 1049), %
or mean  s.d.
Patients with
noncirrhotic fibrosis
at baseline (n = 622),
% or mean  s.d.
Patients with
cirrhosis at baseline
(n = 427), % or
mean  s.d. P-value*
Demographics
Age (years) 50.1  7.2 50.1  7.3 50.1  7.0 0.99
Gender (% female) 29 29 28 0.60
Marital status (% married or living as married) 55 57 53 0.20
Education level (% college graduate) 21 22 19 0.33
Race ⁄ ethnicity (% White, non-Hispanic) 72 72 71 0.81
Body Mass Index (kg ⁄ m2) 29.9  5.5 29.5  5.6 30.3  5.3 0.03
Medical disorders
History of diabetes mellitus (% of patients) 17 16 20 0.08
History of serious or other heart disease
(% of patients)
13 13 13 0.97
History of major depression (% of patients) 7 7 7 0.57
Anxiolytic ⁄ antidepressant use at baseline
(% of patients)
34 34 35 0.76
Hepatitis factors
HCV genotype 1 (% of patients) 94 94 93 0.34
HCV RNA level at baseline (log10 of IU ⁄ mL) 6.4  0.5 6.5  0.5 6.3  0.6 <0.001
Smoking and alcohol use
Ever drank alcohol regularly (% of patients) 83 83 84 0.63
Lifetime alcohol consumption (number of drinks) 18 159  30 881 17 339  30 536 19 359  31 378 0.30
Regular alcohol user at baseline (% of patients) 17 19 14 0.08
Ever smoked cigarettes (% of patients) 76 75 78 0.24
Current smoker at baseline (% of patients) 30 29 31 0.56
Baseline HRQOL and symptom scores
SF-36 Vitality Subscale score 54.2  23.0 55.4  22.3 52.5  23.9 0.05
SF-36 Physical Summary score 44.5  11.3 45.3  11.1 43.4  11.5 0.009
SF-36 Mental Summary score 50.5  9.0 51.1  8.3 49.5  9.9 0.005
Sexual Health score (men only) 74.3  28.4 76.5  27.2 71.2  29.7 0.01
Sexual Health score (women only) 62.9  35.4 64.0  35.8 61.3  34.8 0.53
Fatigue 3.4  2.7 3.3  2.6 3.5  2.8 0.11
General Well-Being 2.7  2.2 2.6  2.2 2.9  2.3 0.13
* P-value for a t-test or chi-squared comparison of participants with baseline noncirrhotic fibrosis vs. participants with
baseline cirrhosis.
 SF-36 and Sexual Health scores have a 100-point scale (0 = worst; 100 = best); Fatigue scores have a 10-point scale (none =
0 to worst ever = 10); and General Well-Being scores have a 10-point scale (very good = 0 to very bad = 10).
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Symptoms
At baseline, self-reported Fatigue and General Well-
Being scores were not significantly different in
participants with fibrosis compared with those with
cirrhosis (Table 1). General Well-Being fluctuated signif-
icantly over time (P = 0.002), but, on average, partici-
pants with fibrosis reported greater General Well-Being
(0.21 units, P = 0.04) than those with cirrhosis (Fig-
ure 2a). Although Fatigue did not change significantly
over time (P = 0.93), participants with fibrosis reported
less Fatigue on average ()0.41 units, P = 0.009) than
those with cirrhosis (Figure 2b). Furthermore, partici-
pants in whom a clinical outcome developed reported
significantly lower General Well-Being ()0.52 units,
P < 0.001) and greater Fatigue (0.60 units, P < 0.001)
compared with patients who did not develop an outcome.
Assignment to the treatment or control group was not
significantly associated with either Fatigue or General
Well-Being scores over time (Figure 2c).
SF-36 scores
At baseline, participants in the cirrhosis stratum had
significantly lower scores on the SF-36 Physical Sum-
mary, Mental Summary and Vitality scales compared
with those in the fibrosis stratum (Table 1). Only the
Physical Summary scores changed significantly over
the course of the study (P = 0.006). On average, partici-
pants with fibrosis reported higher Physical Summary
scores than those with cirrhosis (1.04 points, P = 0.02),
but scores in both groups declined over time (Fig-
ure 3a). Furthermore, the decline in Physical Summary
scores was greater for persons who experienced a clini-
cal outcome than for those who did not ()4.61 points,
P < 0.001). As shown in Figure 3b, participants with a
clinical outcome also had a greater decline in the Men-
tal Summary scores ()1.22 points, P = 0.03) compared
with patients without an outcome. Histological stratum
was not significantly associated with Mental Summary
scores. Participants who experienced a clinical outcome
had a significantly greater decline in Vitality scores
than those who did not ()3.92 points, P < 0.001, Fig-
ure 3c). In addition, participants in the fibrosis stratum
had higher Vitality scores than participants in the cir-
rhosis stratum (3.38 points, P < 0.001).
Vitality scores (Figure 3d) were significantly lower
in participants assigned to the treatment group com-
pared with control participants ()2.88 points,
P = 0.002); after therapy was stopped at month 48,
Vitality scores rebounded to baseline levels and to the
level in the control group. Also, we detected a trend
towards lower Physical Summary scores in the treat-
ment group compared with the control group ()0.84
points, P = 0.06); however, treatment ⁄ control assign-
ment was not significantly associated with Mental
Summary scores (Figure 3e).
Sexual health scores
Figure S1 provides information on the changes from
baseline to 3.5 years by gender and treatment group in
sexual enjoyment, desire and function questions
(Appendix A). In general, approximately half of patients
reported no change over the course of the study.
Compared with control patients, a greater percentage of
treated patients reported a decline over time in sexual
enjoyment (Figure S1a: 35% vs. 24% for men and 32%
vs. 25% for women); sexual desire (Figure S1b: 33% vs.
23% for men and 26% vs. 22% for women); and sexual
function (Figure S1c: 37% vs. 25% for men and 33% vs.
20% for women). Likewise, treated patients were also less
likely to report an improvement over time in enjoyment,
desire and function compared with control patients.
At baseline, men in the cirrhosis stratum had signifi-
cantly lower scores on the composite Sexual Health
Scale compared with men in the fibrosis stratum, while
scores were not significantly different for women (Table
1). The Sexual Health scores declined slightly, but the
change over time was not statistically significant (Table
2). Histological stratum was not significantly associated
with Sexual Health scores in the ANCOVA model. As
shown in Figure 4a, men who experienced a clinical
outcome had lower scores on average than those with-
out outcomes ()11.21 points, P < 0.001). Among men
(Figure 4b), lower Sexual Health scores were seen in the
treatment group compared with the control group
()8.70 points, P < 0.001). The majority of the decline in
the treated men occurred early, with a minimal decline
thereafter that paralleled the decline in the control
group (P for trend = 0.07). In contrast, women had little
change in mean Sexual Health scores over time and no
significant difference was observed between treated and
control female participants.
Association between histological progression
and changes in HRQOL and symptoms
Among the 476 participants in the noncirrhotic fibro-
sis stratum with at least one follow-up liver biopsy,
HRQOL AND SEXUAL HEALTH IN CHRONIC HEPATIT IS C 725
Aliment Pharmacol Ther 31, 719–734
Published 2010. This article is a US Government work and is in the public domain in the USA.
620 566 532 496 480 423
420 381 342 289 261 231
0 2 8 20 26 29
0 19 36 56 58 56
Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 
Cirrhosis with clinical outcome 
622 570 538 501 484 427
425 383 344 295 263 231
0 2 8 20 26 29
0 19 37 57 60 57
Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 



















Fibrosis without clinical outcome
Fibrosis with clinical outcome
Cirrhosis without clinical outcome
Cirrhosis with clinical outcome
Fibrosis without clinical outcome
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Cirrhosis without clinical outcome




























528 487 460 430 418 378 
512 481 458 431 407 361 
517 485 461 441 411 363 
530 489 466 432 422 381 
Number at risk 
General Well-Being control group 
General Well-Being treatment group 
Fatigue treatment group 










General Well-Being, contol group


















Figure 2. Means of (a) General
Well-Being and (b) Fatigue
scores over time by clinical
outcome and stratum;
(c) Symptoms by treatment
assignment. General Well-
Being scores ranged from 0
(very good) to 10 (very bad).
Fatigue scores ranged from 0
(none) to 10 (worst ever).
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152 (32%) had an increase in Ishak score of ‡2 points
during the study. In multivariate analyses, progression
to cirrhosis was associated with a decrease in Vitality
scores ()2.21 points, P = 0.04), an increase in Fatigue
scores (0.44 units, P = 0.001) and worsening of
General Well-Being scores ()0.31 units, P = 0.003)
during follow-up. In contrast, Physical and Mental
Summary scores and Sexual Health scores did not
change significantly in association with worsening of
fibrosis.
DISCUSSION
In persons with early stages of CHC, symptoms tend to
be mild, and HRQOL is relatively well preserved. How-
ever, these clinical features are often worse in patients
with advanced cirrhosis assessed in cross-sectional
studies. The number of patients with liver disease pro-
gression serially assessed over time has been limited.
In the current analyses from a large prospective
randomized controlled trial of long-term low-dose
Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 
Cirrhosis with clinical outcome 
618 571 542 507 477 420 
426 380 344 297 260 229 
0 2 8 22 26 28 
0 19 38 59 59 57 
618 571 542 507 477 420 
426 380 344 297 260 229 
0 2 8 22 26 28 
0 19 38 59 59 57 
Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 
















































Fibrosis without clinical outcome
Fibrosis with clinical outcome
Cirrhosis without clinical outcome
Cirrhosis with clinical outcome
Fibrosis without clinical outcome
Fibrosis with clinical outcome
Cirrhosis without clinical outcome
Cirrhosis with clinical outcome
(a)
(b)
Figure 3. Means of (a) SF-36 Physical Summary, (b) Mental Summary and (c) Vitality scores over time by clinical outcome
and stratum; (d) SF-36 Vitality scores and (e) Summary Scores by treatment assignment. SF-36 scores range from 0 (worst
score) to 100 (best score).
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621 575 547 509 479 421 
427 383 347 298 261 229 
0 2 8 22 26 28 
0 19 38 59 61 57 
Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 
Cirrhosis with clinical outcome 
Number at risk 
Control group 
Treatment group 
529 488 470 443 413 377 
532 492 471 445 416 378 
516 487 469 443 411 357 
515 484 462 442 409 357 
529 488 470 443 413 377 
515 484 462 442 409 357 
Number at risk 
Mental Summary control group  
Mental Summary treatment group  
Physical Summary control group  
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Fibrosis with clinical outcome
Cirrhosis without clinical outcome
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peginterferon therapy for advanced-stage CHC, HRQOL
was prospectively assessed. Clinical progression of
liver disease was associated with statistically and clini-
cally significant declines in all components of HRQOL.
Symptoms of fatigue were also greater and general
well-being was lower in participants with cirrhosis and
participants who experienced a clinical endpoint. Sim-
ilarly, Physical Summary and Vitality scores were
lower in participants with cirrhosis than in those with
noncirrhotic fibrosis. These findings, while not unex-
pected, provide evidence that the selected instruments
(i.e., the SF-36 and visual analogue symptom scales)
can reliably correlate with important baseline clinical
features of CHC as well as an objective measure of
worsening of disease severity over time.
The current results also demonstrate that mainte-
nance peginterferon therapy was associated with sta-
tistically and clinically significant decreases in Vitality
and Physical Summary scores. Furthermore, men who
received peginterferon reported significant declines in
sexual health that did not rebound after cessation of
treatment, despite minimal worsening of fatigue and
well-being. Mental Summary scores, however, did not
worsen significantly with peginterferon therapy. Our
findings suggest that poor baseline mental health





























Number at risk 
Fibrosis without clinical outcome 
Cirrhosis without clinical outcome 
Fibrosis with clinical outcome 
Cirrhosis with clinical outcome 
436 401 380 353 339 303 
306 274 257 220 195 164 
0 2 5 13 16 21 
0 13 25 40 38 41 
383 351 338 321 305 273 
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Figure 4. Means of (a) Sexual Health scores in males by clinical outcome and stratum, (b) Sexual Summary scores by treat-
ment group and gender over time. Sexual Health scores range from 0 (worst score) to 100 (best score).
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to underlying medical and psychiatric comorbidities
and less to severity of liver disease, whereas the physi-
cal domains of HRQOL assessment reflect disease
severity and progression more reliably. This inference
is supported by the high frequency of anxiolytic ⁄ anti-
depressant medication use as well as the frequent his-
tory of prior alcohol and drug use disorders in the
HALT-C patient population.47 In addition, the low dose
of peginterferon used (without ribavirin) and dose
reductions to maintain treatment tolerability may have
yielded a peginterferon dose that was too low to cause
worsening in mental health scores over time.
Maintenance peginterferon therapy for nonresponder
patients with advanced CHC was not only ineffective
in decreasing disease progression and preventing clini-
cal outcomes,38 but also impaired HRQOL and sexual
health (the latter observed only among men). A similar
decline in symptoms of fatigue and well-being that
distinguished treated patients from untreated control
patients was not identified. Our observation of a treat-
ment-related reduction in HRQOL and sexual health
but not of symptoms suggests that the clinical instru-
ment used to assess symptoms was less sensitive than
the SF-36 instrument used to measure HRQOL. Alter-
natively, the less pronounced effects of therapy on
symptoms may have resulted from the fact that pegin-
terferon doses could be reduced because of severe fati-
gue and other drug side effects, which could have
blunted the intensity and duration of treatment-related
symptoms. Similarly, symptom scores did not improve
significantly after month 48, when patients still taking
low-dose peginterferon stopped treatment per protocol.
Previous studies have shown that HRQOL is poor
among patients with CHC compared with uninfected
population controls and is substantially impaired in
patients with histologically documented cirrho-
sis.5, 6, 8–10, 12, 13 A recent prospective study demon-
strated that higher HRQOL predicted lower mortality in
patients with cirrhosis awaiting liver transplantation.48
The current prospective study supports the previous
studies, demonstrating that HRQOL declines when cir-
rhosis develops and declines further when disease
complications and decompensation occur in patients
with cirrhosis. Mean SF-36 scores were consistently
lower in HALT-C patients than scores for age-matched
general US population norms.43, 44 Thus, our findings
support use of changes in HRQOL as a variable of
interest in subsequent clinical trials of maintenance
therapies for CHC. In previous analyses of the lead-in
phase of HALT-C, HRQOL worsened significantly during
full-dose peginterferon and ribavirin therapy and
improved back to baseline levels when treatment was
stopped. Furthermore, patients with an SVR had
improvements in HRQOL to levels that exceeded their
baseline.22 The results of the current analyses support
the importance of changes in HRQOL as a potential
surrogate marker for liver disease progression in
patients with CHC followed up over several years.
The shortcomings of the current analyses include the
limited range of disease severity among the HALT-C
cohort, in that all enrolled participants had advanced
fibrosis and did not have a response to previous antivi-
ral treatment. No participants with early or intermediate
stages of disease and no treatment naı̈ve patients were
included to assess whether HRQOL or symptoms worsen
over time with or without peginterferon therapy. Still,
in participants who had noncirrhotic fibrosis at the start
of therapy and who did not progress to cirrhosis histo-
logically, symptoms and HRQOL were stable, suggesting
that these instruments are reliable markers for disease
progression or its absence in late stages of CHC.
Another shortcoming of the current study was the use
of a sexual health assessment instrument that had not
been validated in other studies or the general popula-
tion. The Sexual Health Scale used in this trial was cal-
culated from three questions regarding sexual
enjoyment, desire and function. Men reported lower
Sexual Health Scale scores while receiving maintenance
peginterferon therapy. However, the scale will need val-
idation before it can be used widely for the sexual
health. The gender differences in sexual health compo-
nents noted in the current analyses are consistent with
previous studies.36 However, the greater impact of treat-
ment and disease progression on Sexual Health scores
in men could be attributable to differing side-effect pro-
files of peginterferon or hormonal changes with liver
disease progression in men compared with women.
Changes in usage of antihypertensive or antidepressant
medications over time were not included in the analyses
and could have been potential confounders.
In summary, our study findings indicate that the
physical components of HRQOL and sexual health (in
men) decline during low-dose, long-term peginterferon
therapy. In addition, clinical progression of disease is
associated with lower SF-36 Physical and Mental
Summary scores and worsening of Fatigue and
General Well-Being over 54 months of follow-up.
These results help validate the utility of the selected
instruments in detecting clinically significant symp-
toms and changes in HRQOL over time in patients with
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Aliment Pharmacol Ther 31, 719–734
Published 2010. This article is a US Government work and is in the public domain in the USA.
chronic liver disease and provide support for their use
as a tool for monitoring disease progression in future
longitudinal studies of CHC.
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27 Häuser W, Zimmer C, Schiedermaier P,
Grandt D. Biopsychosocial predictors of
health-related quality of life in patients
with chronic hepatitis C. Psychosom Med
2004; 66: 954–8.
28 Hunt CM, Dominitz JA, Bute BP, Waters
B, Blasi U, Williams DM. Effect of inter-
feron-alpha treatment of chronic hepatitis
C on health-related quality of life. Dig
Dis Sci 1997; 42: 2482–6.
29 Hussain KB, Fontana RJ, Moyer CA, Su
GL, Sneed-Pee N, Lok ASF. Comorbid ill-
ness is an important determinant of
health-related quality of life in patients
with chronic hepatitis C. Am J Gastroen-
terol 2001; 96: 2737–44.
30 McHutchison J, Ware JE Jr, Bayliss MS,
et al. The effects of interferon alpha-2b in
combination with ribavirin on health
related quality of life and work produc-
tivity. J Hepatol 2001; 34: 140–7.
31 Neary MP, Cort S, Bayliss MS, Ware JE
Jr. Sustained virologic response is associ-
ated with improved health-related quality
of life in relapsed chronic hepatitis C
patients. Semin Liver Dis 1999; 19(Suppl
1): 77–85.
32 Perrillo R, Rothstein KD, Rubin R, et al.
Comparison of quality of life, work pro-
ductivity and medical resource utilization
of peginterferon alpha 2a vs the combina-
tion of interferon alpha 2b plus ribavirin
as initial treatment in patients with
chronic hepatitis C. J Viral Hepat 2004;
11: 157–65.
33 Wessely S, Pariante C. Fatigue, depression
and chronic hepatitis C infection. Psychol
Med 2002; 32: 1–10.
34 Helbling B, Overbeck K, Gonvers JJ, et al.
Host- rather than virus-related factors
reduce health-related quality of life in
hepatitis C virus infection. Gut 2008; 57:
1597–603.
35 Arora S, O’Brien C, Zeuzem S, et al.
Treatment of chronic hepatitis C patients
with persistently normal alanine amino-
transferase levels with the combination of
peginterferon alpha-2a (40 kDa) plus
ribavirin: impact on health-related quality
of life. J Gastroenterol Hepatol 2006; 21:
406–12.
36 Danoff A, Khan O, Wan DW, et al. Sexual
dysfunction is highly prevalent among
men with chronic hepatitis C virus infec-
tion and negatively impacts health-related
quality of life. Am J Gastroenterol 2006;
101: 1235–43.
37 Dove LM, Rosen RC, Ramcharran D, et al.
Decline in male sexual desire, function,
and satisfaction during and after antiviral
therapy for chronic hepatitis C. Gastroen-
terology 2009; 137: 873–84, 884.e1.
38 Di Bisceglie AM, Shiffman ML, Everson
GT, et al. Prolonged therapy of advanced
chronic hepatitis C with low-dose pegin-
terferon. N Engl J Med 2008; 359: 2429–
41.
39 Lee WM, Dienstag JL, Lindsay KL, et al.
Evolution of the HALT-C Trial: pegylated
interferon as maintenance therapy for
chronic hepatitis C in previous interferon
nonresponders. Control Clin Trials 2004;
25: 472–92.
40 Ishak K, Baptista A, Bianchi L, et al. His-
tological grading and staging of chronic
hepatitis. J Hepatol 1995; 22: 696–9.
41 Shiffman ML, Di Bisceglie AM, Lindsay
KL, et al. Peginterferon alfa-2a and riba-
virin in patients with chronic hepatitis C
who have failed prior treatment. Gastro-
enterology 2004; 126: 1015–23.
42 Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC, R W. Transection of the
oesophagus for bleeding oesophageal var-
ices. Br J Surg 1973; 60: 646–9.
43 Ware JE Jr, Snow KK, Kosinski M, Gand-
ek B. SF-36 Health Survey Manual and
Interpretation Guide. Boston, MA: The
Health Institute, New England Medical
Center, 1993.
44 Ware JE Jr, Kosinski M, Keller SD. SF-36
Physical and Mental Summary Scales: A
User’s Manual. Boston, MA: The Health
Institute, New England Medical Center,
1994.
45 Hoofnagle JH, Ghany MG, Kleiner DE,
et al. Maintenance therapy with ribavirin
in patients with chronic hepatitis C who
fail to respond to combination therapy
with interferon alfa and ribavirin. Hepa-
tology 2003; 28: 66–74.
46 Vonesh E, Chinchilli V, Pu K. Goodness-
of-fit in generalized nonlinear mixed-
effects models. Biometrics 1996; 52: 572–
87.
47 Fontana RJ, Bieliauskas LA, Lindsay KL,
et al. Cognitive function does not worsen
during pegylated interferon and ribavirin
retreatment of chronic hepatitis C. Hepa-
tology 2007; 45: 1154–63.
48 Kanwal F, Gralnek IM, Hays R, et al.
Health-related quality of life predicts
mortality in patients with advanced
chronic liver disease. Clin Gastroenterol
Hepatol 2009; 7: 793–9.
732 K . K . SNOW et al.
Aliment Pharmacol Ther 31, 719–734
Published 2010. This article is a US Government work and is in the public domain in the USA.
APPENDIX A
Symptoms form
Mark each line with an "x" that best describes how you have felt during the past 
week. Place an “x” on each line below . (   )
None Worst e ver 
a. Fatigue  
b. Nausea 
c. Pain over the liver
area
d. Poor appetite 
e. Headaches  
f. Muscle/joint aches or 
pains   
g. Itchiness  
h. Irritability  
i. Depression/Sadness
Mark with an “x” the place on the line below that best indicates how you 
feel overall .
Very Good Very Bad
Sexual Health Scale items
Mean score on the following three questions if answered
1–5 (transformed to a 0–100 scale):
How much of the time during the last four weeks, have
you …
• Felt your health interfered with your enjoyment of sex?
• Lacked interest in sex?











1 2 3 4 5 )1
APPENDIX B
University of Massachusetts Medical Center, Worcester,
MA: (Contract N01-DK-9-2326) Gyongyi Szabo, MD,
Barbara F. Banner, MD, Maureen Cormier, RN, Donna
Giansiracusa, RN.
University of Connecticut Health Center, Farming-
ton, CT: (Grant M01RR-06192) Gloria Borders, RN,
Michelle Kelley, RN, ANP.
Saint Louis University School of Medicine, St Louis,
MO: (Contract N01-DK-9-2324) Bruce Bacon, MD,
Brent Neuschwander-Tetri, MD, Elizabeth M. Brunt,
MD, Debra King, RN.
Massachusetts General Hospital, Boston, MA:
(Contract N01-DK-9-2319, Grant M01RR-01066; Grant
1 UL1 RR025758-01, Harvard Clinical and Transla-
tional Science Center) Raymond T. Chung, MD, Andrea
E. Reid, MD, Atul K. Bhan, MD, Wallis A. Molchen,
Cara C. Gooch.
University of Colorado School of Medicine, Denver,
CO: (Contract N01-DK-9-2327, Grant M01RR-00051,
Grant 1 UL1 RR 025780-01) Gregory T. Everson, MD,
S. Russell Nash, MD, Jennifer DeSanto, RN, Carol
McKinley, RN.
University of California – Irvine, Irvine, CA: (Con-
tract N01-DK-9-2320, Grant M01RR-00827) John C.
Hoefs, MD, John R. Craig, MD, M. Mazen Jamal, MD,
MPH, Muhammad Sheikh, MD, Choon Park, RN.
University of Texas Southwestern Medical Center,
Dallas, TX: (Contract N01-DK-9-2321, Grant M01RR-
00633, Grant 1 UL1 RR024982-01, North and Central
Texas Clinical and Translational Science Initiative)
William M. Lee, MD, Thomas E. Rogers, MD, Peter F.
Malet, MD, Janel Shelton, Nicole Crowder, LVN, Rivka
Elbein, RN, BSN, Nancy Liston, MPH.
University of Southern California, Los Angeles, CA:
(Contract N01-DK-9-2325, Grant M01RR-00043) Karen
L. Lindsay, MD, MMM, Sugantha Govindarajan, MD,
Carol B. Jones, RN, Susan L. Milstein, RN.
University of Michigan Medical Center, Ann Arbor,
MI: (Contract N01-DK-9-2323, Grant M01RR-00042,
Grant 1 UL1 RR024986, Michigan Center for Clinical
and Health Research) Anna S. Lok, MD, Joel K. Green-
son, MD, Pamela A. Richtmyer, LPN, CCRC, R. Tess
Bonham, BS.
Virginia Commonwealth University Health System,
Richmond, VA: (Contract N01-DK-9-2322, Grant
M01RR-00065) Mitchell L. Shiffman, MD, Melissa J.
Contos, MD, A. Scott Mills, MD, Charlotte Hofmann,
RN, Paula Smith, RN.
Liver Diseases Branch, National Institute of Diabetes
and Digestive and Kidney Diseases, National Institutes
of Health, Bethesda, MD: T. Jake Liang, MD, David
Kleiner, MD, PhD, Yoon Park, RN, Elenita Rivera, RN,
Vanessa Haynes-Williams, RN.
HRQOL AND SEXUAL HEALTH IN CHRONIC HEPATIT IS C 733
Aliment Pharmacol Ther 31, 719–734
Published 2010. This article is a US Government work and is in the public domain in the USA.
National Institute of Diabetes and Digestive and Kid-
ney Diseases, Division of Digestive Diseases and Nutri-
tion, Bethesda, MD: Jay H. Hoofnagle, MD, James E.
Everhart, MD, Leonard B. Seeff, MD, Patricia R. Ro-
buck, PhD, Elizabeth C. Wright, PhD.
University of Washington, Seattle, WA: (Contract
N01-DK-9-2318) Chihiro Morishima, MD, David
R. Gretch, MD, PhD, Minjun Chung Apodaca, BS,
ASCP, Rohit Shankar, BC, ASCP, Natalia Antonov, M.
Ed.
New England Research Institutes, Watertown, MA:
(Contract N01-DK-9-2328) Anne M. Stoddard, ScD,
Teresa M. Curto, MSW, MPH, Margaret C. Bell, MS,
MPH, Raymond C. Rosen, PhD.
Armed Forces Institute of Pathology, Washington,
DC: Zachary D. Goodman, MD.
Data and Safety Monitoring Board Members: (Chair)
Gary L. Davis, MD, Guadalupe Garcia-Tsao, MD,
Michael Kutner, PhD, Stanley M. Lemon, MD, Robert
P. Perrillo, MD.
734 K . K . SNOW et al.
Aliment Pharmacol Ther 31, 719–734
Published 2010. This article is a US Government work and is in the public domain in the USA.
